Skip to content

The Study of the Effectiveness of the Plaque-RADS Classification System in Evaluating Carotid Artery Plaques in Patients with Embolic Stroke of Undetermined Source

The Study of the Effectiveness of the Plaque-RADS Classification System in Evaluating Carotid Artery Plaques in Patients with Embolic Stroke of Undetermined Source

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124572
Enrollment
Unknown
Registered
2026-05-14
Start date
2025-09-11
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute unilateral anterior circulation ESUS

Interventions

High-grade Plaque-RADS plaque group:None

Sponsors

Jiangbin Hospital, Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with acute unilateral anterior circulation ESUS; 2. Age >= 35 years; 3. Presence of carotid artery plaque confirmed by imaging examinations; 4. No history of cervical vascular surgery; 5. Patient informed consent obtained; 6. Subjects have no contraindications and can safely undergo imaging examinations including ultrasound (US), computed tomography angiography (CTA), and magnetic resonance imaging (MRI).

Exclusion criteria

Exclusion criteria: 1.Presence of severe liver, kidney, heart, lung, or gastrointestinal diseases; 2. History of cervical vascular surgical treatments, such as carotid endarterectomy, carotid stenting, or vascular bypass surgery; 3. Intracranial or extracranial arterial occlusion caused by various reasons; 4. Patients with stroke events caused by other clear etiologies, such as patent foramen ovale, cardiac valvular disease, myocarditis, atrial fibrillation, or intracranial arterial stenosis; 5. Contraindications to imaging examinations, allergy to contrast agents, or absolute contraindications to MRI examination (e.g., non-removable metal implants in the body); 6. Inability to cooperate with the study or an estimated survival period of less than 12 months; 7. Incomplete hospitalization information or incomplete clinical follow-up data.

Design outcomes

Primary

MeasureTime frame
Cross-modal consistency;Difference in proportion of high-risk plaques on the same side;Prediction performance difference from traditional methods;

Countries

China

Contacts

Public ContactWei Jiezhi

Jiangbin Hospital, Guangxi Zhuang Autonomous Region

44086489@qq.com+86 771 2114481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026